EGI
PTGX icon

EAM Global Investors’s Protagonist Therapeutics PTGX Stock Holding History

EAM Global Investors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-69,726
Closed -$3.85M – 58
2025
Q2 		$3.85M Sell
69,726
-24
-0% -$1.15K 1% 64
2025
Q1 		$3.37M Buy
+69,750
New +$2.92M 0.92% 68
2021
Q3 		– Sell
-70,185
Closed -$3.15M – 230
2021
Q2 		$3.15M Buy
+70,185
New +$2.32M 0.87% 20
2021
Q1 		– Sell
-62,047
Closed -$1.25M – 178
2020
Q4 		$1.25M Sell
62,047
-44,288
-42% -$953K 0.34% 125
2020
Q3 		$2.08M Buy
+106,335
New +$2M 0.76% 54

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EAM Global Investors's PTGX Position: Q3 2025 in Review

EAM Global Investors sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 69,726 shares — an estimated $3.85M sold.

EAM Global Investors first reported a position in PTGX in Q3 2020 and held it in 5 quarters. The position peaked at $3.85M in Q2 2025. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • EAM Global Investors reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EAM Global Investors sold 69,726 Protagonist Therapeutics shares in Q3 2025, an estimated $3.85M.
  • EAM Global Investors first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 5 quarters.
  • EAM Global Investors's Protagonist Therapeutics position peaked at $3.85M in Q2 2025.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on EAM Global Investors's 13F filing for Q3 2025, filed 14 Nov 2025.